Skip to main content

Exposure to Hydroxyurea Does Not Impact Ovarian Reserve in Sickle Cell

Medically reviewed by Carmen Pope, BPharm. Last updated on July 25, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, July 25, 2024 -- For girls and young women with sickle cell disease (SCD), exposure to hydroxyurea does not reduce ovarian reserve, according to a study published online July 18 in Blood Advances.

Tamara Diesch-Furlanetto, Ph.D., from the University of Basel Children's Hospital in Switzerland, and colleagues counted follicles and categorized them based on their growth stage by analyzing digitized slides of ovarian tissue from girls and young women with SCD who underwent ovarian tissue cryopreservation (OTC) before hematological stem cell transplantation. The densities of different follicle types were calculated and their correlation with patient characteristics, clinical manifestations, and treatments was assessed. A total of 76 SCD patients were included in the study (median age at OTC, 10.2 years); 50 were prepubertal.

Thirty-five of the patients had received hydroxyurea. The researchers found that the primordial follicle density was comparable in the hydroxyurea and non-hydroxyurea groups (5.8 versus 4.2 follicles/mm2). After adjustment for age, the density of growing follicles was marginally lower in the hydroxyurea versus the non-hydroxyurea group. Other parameters, including vaso-occlusive crisis (VOC), did not impact the follicular density.

"These findings indicate that ovarian reserve in SCD was not reduced by HU [hydroxyurea] treatment, transfusion, or VOC. Therefore, OTC should be considered as a fertility preservation option before gonadotoxic treatment for this population," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted July 2024

Read this next

Hydroxyurea Has Sustained Clinical Benefits in Children With Sickle Cell Anemia

TUESDAY, April 29, 2025 -- For children with sickle cell anemia (SCA), hydroxyurea has sustained clinical benefits in terms of reducing emergency department visits and hospital...

C-Reactive Protein Increases During Menstrual Cycle in Females With Sickle Cell Disease

TUESDAY, April 15, 2025 -- For adults with sickle cell disease (SCD), C-reactive protein (CRP) levels increase significantly during the follicular phase of the menstrual cycle...

Recommendations Updated for Fertility Preservation in Cancer

THURSDAY, April 10, 2025 -- In a special article published online March 19 in the Journal of Clinical Oncology, the American Society of Clinical Oncology presents updated...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.